Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4758470 | 0.76 | CDK5 (0.41) | CDK5DYRK1AGRM5CDK5R1ALDH1A1 | |
| SCHEMBL23500956 | 0.74 | KDM4E (0.41) | CDK5DYRK1AGRM5ALDH1A1HTT | |
| SCHEMBL6218467 | 0.73 | ALDH1A1 (0.40) | ALDH1A1HTTADORA2AADORA1KDM4E | |
| SCHEMBL5331431 | 0.69 | MAPK1 (0.58) | CDK5DYRK1AGRM5CDK5R1ALDH1A1 | |
| SCHEMBL6071941 | 0.68 | KDM4E (0.47) | ALDH1A1HTTADORA2AADORA1KDM4E | |
| SCHEMBL8993033 | 0.66 | MAPK1 (0.53) | CDK5ALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL10700367 | 0.65 | TSHR (0.54) | ALDH1A1 | |
| SCHEMBL17071852 | 0.65 | TSHR (0.54) | ALDH1A1 | |
| SCHEMBL17071848 | 0.65 | TSHR (0.54) | ALDH1A1 | |
| SCHEMBL6071934 | 0.65 | KDM4E (0.47) | ALDH1A1HTTADORA2AADORA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470698-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070249641-A1 | ADENOSINE A3 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2007-10-25 | — | — | US | disclosed |
| US-7271171-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060040959-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-02-23 | — | — | US | disclosed |
| EP-1499614-A4 | ADENOSINE A3 RECEPTOR MODULATORS | KING PHARMACEUTICALS RES & DEV (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6921825-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICUALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1499614-A1 | ADENOSINE A3 RECEPTOR MODULATORS | King Pharmaceuticals Research and Development Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003095457-A1 | ADENOSINE A3 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| US-20030144266-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-07-31 | — | — | US | disclosed |
| US-6448253-B1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6407236-B1 | TUMOR DIAGNOSIS; ANTIINFLAMMATORY AGENTS; ANTIISCHEMIC AGENTS; ANTIDEPRESSANTS | MEDCO RESEARCH, INC. | 2002-06-18 | — | — | US | disclosed |
| WO-1995001356-A1 | 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES HAVING ANTAGONISTIC ACTIVITY ON ADENOSINE A2 RECEPTOR | SCHERING-PLOUGH S.P.A. (IT) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040959-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | CDK5 1886/4885DYRK1A 2469/4885GRM5 905/4885 |
| US-20070249641-A1 | ADENOSINE A3 RECEPTOR MODULATORS | ADORA3, ADORA2A, ADORA1 | CDK5 1886/4885DYRK1A 2469/4885GRM5 905/4885 |
| US-20030144266-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | CDK5 2297/4885DYRK1A 2359/4885GRM5 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.